Research Paper Volume 15, Issue 16 pp 7997—8012
HYDIN mutation status as a potential predictor of immune checkpoint inhibitor efficacy in melanoma
Figure 2. HYDIN mutations were related to better clinical outcomes in the anti-PD-1 treated cohort. The Kaplan–Meier curves of overall survival in the anti-PD-1 treated cohort (A) and the TCGA-SKCM cohort (B). Histogram depicting proportions of ORR (C) and DCB (D) in HYDIN-MUT and HYDIN-WT patients in the anti-PD-1 treated cohort. DCB, durable clinical benefit; ORR, objective response rate; HYDIN-MUT, HYDIN mutations; HYDIN-WT, HYDIN wild-type; Anti-PD-1, anti-programmed cell death protein 1.